Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
L04AA10 SIROLIMUS COMPR. FILM. 1 mg
RAPAMUNE 1 mg 1 mg WYETH EUROPA LTD.
________________________________________________________________________________
______________________________________________________________________________
| 1034 |L04AX01| AZATHIOPRINUM* | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
L04AX01 AZATHIOPRINUM COMPR. FILM. 50 mg
IMURAN(R) 50 mg THE WELLCOME FOUNDATION
LTD.
________________________________________________________________________________
SUBLISTA C2 - P10: PROGRAM NAŢIONAL DE SUPLEERE A FUNCŢIEI RENALE LA BOLNAVII CU INSUFICIENŢĂ RENALĂ CRONICĂ.
______________________________________________________________________________
| 1035 |A11CC03| ALFACALCIDOLUM | Protocol: A007E |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
A11CC03 ALFACALCIDOLUM CAPS. MOI 0.25 µg
ALPHA D3 0,25 µg 0.25 µg TEVA PHARMACEUTICALS SRL
A11CC03 ALFACALCIDOLUM CAPS. MOI 0.50 µg
ALPHA D3 0.50 µg 0.50 µg TEVA PHARMACEUTICALS SRL
________________________________________________________________________________
______________________________________________________________________________
| 1036 |A11CC04| CALCITRIOLUM** | Protocol: A006E |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
A11CC04 CALCITRIOLUM CAPS. MOI 0.25 µg
ROCALTROL 0.25 µg ROCHE ROMANIA S.R.L.
________________________________________________________________________________
______________________________________________________________________________
| 1037 |A11CC07| PARICALCITOLUM** | Protocol: A005E |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
A11CC07 PARICALCITOLUM SOL. INJ. 5 µg/ml
ZEMPLAR 5 µg/ml ABBOTT LABORATORIES S.A.
________________________________________________________________________________
______________________________________________________________________________
| 1038 |B01AB01| HEPARINUM** | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
B01AB01 HEPARINUM SOL. INJ. 5000 ui/ml
HEPARIN 5000 ui/ml POLIPHARMA INDUSTRIES
S.R.L.
HEPARIN SANDOZ(R) 5000 ui/ml SANDOZ GMBH
25000 UI/5 ml
HEPARINE SODIQUE PANPHARMA 5000 ui/ml LAB. PANPHARMA
________________________________________________________________________________
______________________________________________________________________________
| 1039 |B01AB05| ENOXAPARINUM** | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
B01AB05 ENOXAPARINUM SOL. INJ. 2000 ui
anti - Xa/0.2 ml
CLEXANE 2000 ui
anti - Xa/0.2 ml 2000 ui LAB. AVENTIS
anti - Xa/0.2 ml
B01AB05 ENOXAPARINUM SOL. INJ. 4000 ui
anti - Xa/0,4 ml
CLEXANE 4000 ui
anti - Xa/0.4 ml 4000 ui LAB. AVENTIS
anti - Xa/0,4 ml
B01AB05 ENOXAPARINUM SOL. INJ. 6000 ui
anti - Xa/0.6 ml
CLEXANE 6000 ui 6000 ui LAB. AVENTIS
anti - Xa/0.6 ml anti - Xa/0.6 ml
B01AB05 ENOXAPARINUM SOL. INJ. 8000 ui
anti - Xa/0.8 ml
CLEXANE 8000 ui 8000 ui LAB. AVENTIS
anti - Xa/0.8 ml anti - Xa/0.8 ml
B01AB05 ENOXAPARINUM SOL. INJ. 2000 ui
anti - Xa/0.2 ml
CLEXANE 2000 ui 2000 ui LAB. AVENTIS
anti - Xa/0.2 ml anti - Xa/0.2 ml
B01AB05 ENOXAPARINUM SOL. INJ. 4000 ui
anti - Xa/0,4 ml
CLEXANE 4000 ui 4000 ui LAB. AVENTIS
anti - Xa/0.4 ml anti - Xa/0,4 ml
B01AB05 ENOXAPARINUM SOL. INJ. 6000 ui
anti - Xa/0.6 ml
CLEXANE 6000 ui 6000 ui LAB. AVENTIS
anti - Xa/0.6 ml anti - Xa/0.6 ml
________________________________________________________________________________
______________________________________________________________________________
| 1040 |B01AB06| NADROPARINUM** | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
B01AB06 NADROPARINUM SOL. INJ. 11400 ui AXa/0.6 ml
FRAXODI 11400 UI 11400 ui AXa/0.6 ml GLAXO GROUP LTD.
anti - factor Xa/0,6 ml
B01AB06 NADROPARINUM SOL. INJ. 15200 ui AXa/0.8 ml
FRAXODI 15200 UI 15200 ui AXa/0.8 ml GLAXO GROUP LTD.
anti - factor Xa/0,8 ml
B01AB06 NADROPARINUM SOL. INJ. 2850 ui AFXa/0.3 ml
FRAXIPARINE(R) 2850 UI 2850 ui AFXa/0.3 ml GLAXO GROUP LTD.
anti - factor Xa/0,3 ml
B01AB06 NADROPARINUM SOL. INJ. 3800 ui AFXa/0.4 ml
FRAXIPARINE(R) 3800 UI 3800 ui AFXa/0.4 ml GLAXO GROUP LTD.
anti - factor Xa/0,4 ml
B01AB06 NADROPARINUM SOL. INJ. 5700 ui AFXa/0.6 ml
FRAXIPARINE(R) 5700 UI 5700 ui AFXa/0.6 ml GLAXO GROUP LTD.
anti - factor Xa/0,6 ml
B01AB06 NADROPARINUM SOL. INJ. 7600 ui AXa/0.8 ml
FRAXIPARINE(R) 7600 UI 7600 ui AXa/0.8 ml GLAXO GROUP LTD.
anti - factor Xa/0,8 ml
________________________________________________________________________________
______________________________________________________________________________
| 1041 |B01AB08| REVIPARINUM** | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
B01AB08 REVIPARINUM SOL. INJ. 1432 ui/0.25 ml
CLIVARIN(R) 1432 UI/0.25 ml 1432 ui/0.25 ml ABBOTT GMBH & CO. KG
B01AB08 REVIPARINUM SOL. INJ. 3436 ui/0.6 ml
CLIVARIN(R) 3436 UI/0,6 ml 3436 ui/0.6 ml ABBOTT GMBH & CO. KG
________________________________________________________________________________
______________________________________________________________________________
| 1042 |B01AB10| TINZAPARINUM** | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
B01AB10 TINZAPARINUM SOL. INJ. 10000 u ANTIF. Xa/ml
INNOHEP 10000 U ANTIF. Xa/ml LEO PHARMACEUTICAL
PRODUCTS
B01AB10 TINZAPARINUM SOL. INJ. 20000 u ANTIF. Xa/ml
INNOHEP 20000 U ANTIF. Xa/ml LEO PHARMACEUTICAL
PRODUCTS
________________________________________________________________________________
______________________________________________________________________________
| 1043 |B03AC02| COMPLEX DE HIDROXID DE FER (III) SUCROZA | Protocol: A010N |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
B03AC02 COMPLEX DE HIDROXID SOL. INJ./PERF. 20 mg/ml
DE FER (III) SUCROZA
VENOFER(R) 20 mg/ml VIFOR FRANCE S.A.
________________________________________________________________________________
______________________________________________________________________________
| 1044 |B03XA01| EPOETINUM ALFA** | Protocol: B010N |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
B03XA01 EPOETINUM ALFA SOL. INJ. 10000 ui/ml
EPREX(R) 10000 UI 10000 ui/ml JOHNSON & JOHNSON D.O.O.
B03XA01 EPOETINUM ALFA SOL. INJ. IN SERINGA 1000 UI/0,3 ml
PREUMPLUTA
EPREX(R) 1000 UI 1000 ui/0.5 ml JOHNSON & JOHNSON D.O.O.
B03XA01 EPOETINUM ALFA SOL. INJ. IN SERINGA 1000 UI/0,5 ml
PREUMPLUTA
BINOCRIT 1000 UI/0,5 ml 1000 UI/0,5 ml SANDOZ GMBH
EPOKINE 1000 UI/0,5 ml 1000 UI/0.5 ml RENAMED FARMA S.R.L.
B03XA01 EPOETINUM ALFA SOL. INJ. IN SERINGA 20000 UI/0,5 ml
PREUMPLUTA
EPOKINE 2000 UI/0,5 ml 2000 UI/0.5 ml RENAMED FARMA S.R.L.
B03XA01 EPOETINUM ALFA SOL. INJ. 2000 UI
EPOPHAR 2000 U.I. 2000 UI GULF PHARMACEUTICAL IND.
S.R.L.
EPREX(R) 2000 UI 2000 ui/0.5 ml JOHNSON & JOHNSON D.O.O.
B03XA01 EPOETINUM ALFA SOL. INJ. IN SERINGA 2000 UI/1,0 ml
PREUMPLUTA
BINOCRIT 2000 UI/1,0 ml 2000 UI/1,0 ml SANDOZ GMBH
EPOKINE 2000 UI/1 ml 2000 UI/1 ml RENAMED FARMA S.R.L.
B03XA01 EPOETINUM ALFA SOL. INJ. IN SERINGA 3000 UI/0,3 ml
PREUMPLUTA
BINOCRIT 3000 UI/0,3 ml 3000 UI/0,3 ml SANDOZ GMBH
B03XA01 EPOETINUM ALFA SOL. INJ. 3000 ui/0.3 ml
EPREX(R) 3000 UI 3000 ui/0.3 ml JOHNSON & JOHNSON D.O.O.
B03XA01 EPOETINUM ALFA SOL. INJ. 40000 UI
EPREX(R) 40000 UI 40000 UI JOHNSON & JOHNSON D.O.O.
B03XA01 EPOETINUM ALFA SOL. INJ. 4000 UI
EPOPHAR 4000 UI 4000 UI GULF PHARMACEUTICAL IND.
S.R.L.
B03XA01 EPOETINUM ALFA SOL. INJ. IN SERINGA 4000 UI/0,4 ml
PREUMPLUTA
BINOCRIT 4000 UI/0,4 ml 4000 UI/0,4 ml SANDOZ GMBH
EPOKINE 4000 UI/0,4 ml 4000 UI/0.4 ml RENAMED FARMA S.R.L.
EPREX(R) 4000 UI 4000 ui/0.4 ml JOHNSON & JOHNSON D.O.O.
B03XA01 EPOETINUM ALFA SOL. INJ. 4000 UI/1 ml
EPOKINE 4000 UI/1 ml 4000 UI/1 ml RENAMED FARMA S.R.L.
________________________________________________________________________________
______________________________________________________________________________
| 1045 |B03XA01| EPOETINUM BETA** | Protocol: B009N |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
B03XA01 EPOETINUM BETA SOL. INJ. IN SERINGA 10000 UI/0,6 ml
PREUMPLUTA
NEORECORMON 10000 UI/0,6 ml 10000 UI/0,6 ml ROCHE REGISTRATION LTD.
B03XA01 EPOETINUM BETA SOL. INJ. IN SERINGA 1000 UI/0,3 ml
PREUMPLUTA
NEORECORMON 1000 UI/0,3 ml 1000 UI/0,3 ml ROCHE REGISTRATION LTD.
B03XA01 EPOETINUM BETA SOL. INJ. IN SERINGA 2000 UI/0,3 ml
PREUMPLUTA
NEORECORMON 2000 UI/0,3 ml 2000 UI/0,3 ml ROCHE REGISTRATION LTD.
B03XA01 EPOETINUM BETA SOL. INJ. IN SERINGA 4000 UI/0,3 ml
PREUMPLUTA
NEORECORMON 4000 UI/0,3 ml 4000 UI/0,3 ml ROCHE REGISTRATION LTD.
B03XA01 EPOETINUM BETA SOL. INJ. IN SERINGA 5000 UI/0,3 ml
PREUMPLUTA
NEORECORMON 5000 UI/0,3 ml 5000 UI/0,3 ml ROCHE REGISTRATION LTD.
B03XA01 EPOETINUM BETA SOL. INJ. IN SERINGA 500 UI/0,3 ml
PREUMPLUTA
NEORECORMON 500 UI/0,3 ml 500 UI/0,3 ml ROCHE REGISTRATION LTD.
________________________________________________________________________________
______________________________________________________________________________
| 1046 |B03XA02| DARBEPOETINUM ALFA** | Protocol: B011N |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
B03XA02 DARBEPOETINUM ALFA SOL. INJ. IN SERINGA 10 µg/0,4 ml
PREUMPLUTA
ARANESP 10 µg/0.4 ml 10 µg/0.4 ml AMGEN EUROPE BV
B03XA02 DARBEPOETINUM ALFA SOL. INJ. IN SERINGA 100 µg/0,5 ml
PREUMPLUTA
ARANESP 100 µg/0.5 ml 100 µg/0.5 ml AMGEN EUROPE BV
B03XA02 DARBEPOETINUM ALFA SOL. INJ. IN SERINGA 15 µg/0.375 ml
PREUMPLUTA
ARANESP 15 µg/0.375 ml 15 µg/0.375 ml AMGEN EUROPE BV
B03XA02 DARBEPOETINUM ALFA SOL. INJ. IN SERINGA 150 µg/0,3 ml
PREUMPLUTA
ARANESP 150 µg/0.3 ml 150 µg/0.3 ml AMGEN EUROPE BV
B03XA02 DARBEPOETINUM ALFA SOL. INJ. IN SERINGA 20 µg/0.5 ml
PREUMPLUTA
ARANESP 20 µg/0.5 ml 20 µg/0.5 ml AMGEN EUROPE BV
B03XA02 DARBEPOETINUM ALFA SOL. INJ. IN SERINGA 30 µg/0.3 ml
PREUMPLUTA
ARANESP 30 µg/0.3 ml 30 µg/0.3 ml AMGEN EUROPE BV
B03XA02 DARBEPOETINUM ALFA SOL. INJ. IN SERINGA 300 µg/0.6 ml
PREUMPLUTA
ARANESP 300 µg/0.6 ml 300 µg/0.6 ml AMGEN EUROPE BV
B03XA02 DARBEPOETINUM ALFA SOL. INJ. IN SERINGA 40 µg/0.4 ml
PREUMPLUTA
ARANESP 40 µg/0.4 ml 40 µg/0.4 ml AMGEN EUROPE BV
B03XA02 DARBEPOETINUM ALFA SOL. INJ. IN SERINGA 50 µg/0.5 ml
PREUMPLUTA
ARANESP 50 µg/0.5 ml 50 µg/0.5 ml AMGEN EUROPE BV
B03XA02 DARBEPOETINUM ALFA SOL. INJ. IN SERINGA 500 µg/ml
PREUMPLUTA
ARANESP 500 µg/ml 500 µg/ml AMGEN EUROPE BV
B03XA02 DARBEPOETINUM ALFA SOL. INJ. IN SERINGA 60 µg/0.3 ml
PREUMPLUTA
ARANESP 60 µg/0.3 ml 60 µg/0.3 ml AMGEN EUROPE BV
B03XA02 DARBEPOETINUM ALFA SOL. INJ. IN SERINGA 80 µg/0.4 ml
PREUMPLUTA
ARANESP 80 µg/0.4 ml 80 µg/0.4 ml AMGEN EUROPE BV
________________________________________________________________________________
______________________________________________________________________________
| 1049 |V03AE02| SEVELAMER** | Protocol: V003D |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
V03AE02 SEVELAMER COMPR. FILM. 800 mg
RENAGEL 800 mg 800 mg GENZYME EUROPE BV
________________________________________________________________________________
______________________________________________________________________________
| 1050 |H05BX01| CINACALCETUM**** | Protocol: H003N |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
H05BX01 CINACALCETUM COMPR. FILM. 30 mg
MIMPARA 30 mg 30 mg AMGEN EUROPE B.V.
H05BX01 CINACALCETUM COMPR. FILM. 60 mg
MIMPARA 60 mg 60 mg AMGEN EUROPE B.V.
H05BX01 CINACALCETUM COMPR. FILM. 90 mg
MIMPARA 90 mg 90 mg AMGEN EUROPE B. V.
________________________________________________________________________________
SUBLISTA C2 - P11: PROGRAM NAŢIONAL DE SĂNĂTATE MINTALĂ. SUBPROGRAMUL TRATAMENTUL TOXICODEPENDENŢELOR
______________________________________________________________________________
| 1051 |N07BB04| NALTREXONUM | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
N07BB04 NALTREXONUM COMPR. FILM. 50 mg
REVIA 50 mg TORREX CHIESI PHARMA GMBH
________________________________________________________________________________
Naltrexone hydrochloride este contraindicată la pacienţii trataţi cu medicamente opioide
______________________________________________________________________________
| 1052 |N07BC02| METHADONUM | |
|_______|_______|____________________________________________|_________________|
Risc înalt de apariţie a dependenţei.
Dostları ilə paylaş: |